Benzinga··Globe NewswireMerck to Acquire Terns Pharmaceuticals for $6.7B to Bolster CML Portfolio
Merck acquires Terns Pharmaceuticals for $6.7 billion to gain TERN-701, a novel leukemia treatment, at 31% premium valuation.
MRKTERNacquisitionM&A
tyrosine kinase inhibitor
3 articlesBenzinga··Globe Newswire
GlobeNewswire Inc.··NaCogent Biosciences Presents Expanded SUMMIT Trial Results for Bezuclastinib at 2026 AAAAI Meeting
Cogent Biosciences presented expanded SUMMIT trial data showing bezuclastinib achieved significant symptom reduction and tryptase normalization in systemic mastocytosis patients, supporting its FDA regulatory applications.
COGTdisease modificationclinical results
GlobeNewswire Inc.··Eyepoint, Inc.EyePoint Pharmaceuticals Names Veteran Ophthalmology Executive Campbell as CCO
EyePoint Pharmaceuticals appoints Michael Campbell as Chief Commercial Officer. The ophthalmology veteran brings 30+ years of experience to lead commercial strategy for DURAVYU ahead of 2026 clinical data.
EYPTPhase 3 clinical trialophthalmology